SEC Form 4/A · accession 0001493152-17-010376
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
James C Czirr
Director
Period of report
Dec 31, 2016
Accepted (ET)
Sep 8, 2017 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Dec 31, 2016 | J | 211,876 | $1.01 | A | 2,923,794 | I | By 10X Fund, LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Common stock received in satisfaction of $213,994.83 of dividends due on Series B-1, B-2 and B-3 Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.
- F2This Form 4/A amends a Form 4 originally filed 2/1/2017, which reported the receipt of 211,876 shares as a stock dividend, and is being filed to correct the number of shares owned after receipt of the dividend, which changed as the result of an amendment filed to correct erroneous information in a prior Form 4.
- F3The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.